A Phase 1 interventional study of Budesonide in Healthy Volunteers, sponsored by Sandoz. Completed at 1 site in United Kingdom. Open to participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-23.
Sponsored by Sandoz (formerly part of Novartis) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single centre, open-label, sequential, single dose 4-period crossover, scintigraphic imaging study in healthy male and non-pregnant, non-lactating female subjects.
Subjects will be screened for eligibility to participate in the study up to 28 days before dosing. For each treatment period, subjects will be admitted to the clinical unit on the evening prior to IMP administration (Day -1) and will fast overnight for a minimum of 8 h. On the morning of Day 1, subjects will receive IMP in the fasted state and will remain on site until 24 h post-dose. Following Period 2, there will be an interim analysis and review of safety and scintigraphy data from dosed regimens in order to determine which formulations will be used in subsequent periods. A follow-up phone call will take place 3 to 5 days post-final dose to ensure the ongoing wellbeing of the subjects.
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
First submitted before Sandoz left Novartis.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single dose of 2 mg oral suspension formulation 1 administered orally under fasting conditions
Drug: Budesonide
single dose of 2 mg oral suspension formulation 2 administered orally under fasting conditions
Drug: Budesonide
single dose of 2 mg oral suspension formulation 3 administered orally under fasting conditions
Drug: Budesonide
single dose of 2 mg oral suspension formulation 4 administered orally under fasting conditions
Drug: Budesonide
single dose of 2 mg oral suspension formulation administered orally under fasting conditions
Total oesophageal transit time
A comparison of the in vivo oesophageal transit times of budesonide suspension formulations will be determined using scintigraphic methods.
Time frame: During procedure
Time at which 10% radiolabel administered has arrived in the oesophagus from the mouth (T10%) (min)
A comparison of the in vivo oesophageal transit times of budesonide suspension formulations will be determined using scintigraphic methods.
Time frame: During procedure
Time at which 50% radiolabel administered has arrived in the oesophagus from the mouth (T50%) (min)
A comparison of the in vivo oesophageal transit times of budesonide suspension formulations will be determined using scintigraphic methods.
Time frame: During procedure
Time at which the amount of radiolabel present in the oesophagus peaks (Tmax) (min)
A comparison of the in vivo oesophageal transit times of budesonide suspension formulations will be determined using scintigraphic methods.
Time frame: During procedure
Time at which 90% of the radiolabel present at Tmax has left the oesophagus (T90%) (min)
A comparison of the in vivo oesophageal transit times of budesonide suspension formulations will be determined using scintigraphic methods.
Time frame: During procedure
Total amount of radiolabel present in the oesophagus and the three regions over time
A comparison of the in vivo oesophageal transit times of budesonide suspension formulations will be determined using scintigraphic methods.
Time frame: During procedure
Number of adverse events
Number of adverse events will be provided to get additional information on the safety and tolerability of budesonide suspension formulations after oral administration.
Time frame: throughout the study, approximately 13 weeks
Ran from Dec 2018 to primary completion in Jan 2019, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide